Compositions of a peptide targeting system for treating cancer
AssigneePeptiMed, Inc.
InventorsThomas Primiano, Bey-Dih Chang, Jeremy Heidel
Life of this patent
Estimating the term…
Abstract
This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.
Claims19
An isolated polypeptide comprising an assembly domain (AD), a cell targeting domain (CTD), and a nucleic acid binding domain (NBD), wherein the isolated polypeptide comprises SEQ ID No. 56.
An isolated polypeptide comprising an assembly domain (AD), a cell targeting domain (CTD), and a nucleic acid binding domain (NBD), wherein the CTD comprises SEQ ID No. 19.
A method of targeting a drug agent to a target cell, comprising:
- obtaining one or more polypeptides comprising an assembly domain (AD), a nucleotide binding domain (NBD), and a cell targeting domain (CTD);
- contacting the drug agent with the NBD of one or more polypeptides;
- assembling the AD of one or more polypeptides to generate an assembled polypeptide;
- contacting the assembled polypeptide with the target cell;
- and
- contacting the CTD of the assembled polypeptide with a biological molecule present outside of the target cell,
- wherein one or more of the polypeptides comprises SEQ ID No. 56.
Dependencies are inferred from the claim text.